You are here

SCARAB GENOMICS, LLC

Company Information
Address
1202 Ann St
MADISON, WI 53713-2410
United States


http://www.scarabgenomics.com

Information

UEI: S4XQJDL7DN15

# of Employees: 14


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture

    Amount: $2,906,252.00

    Scarab Genomics’ C-Flow™ technology is a highly efficient continuous culture system that can produce kilograms of protein in a few weeks at a mere 10-liter scale. This project will determine wheth ...

    SBIRPhase II2020Department of Health and Human Services National Institutes of Health
  2. Lysis-free extraction of biopharmaceuticals from the periplasm of Clean Genome E. coli

    Amount: $156,171.00

    Thirty percent of recombinant therapeutic proteins are made in Ecoli and include important vaccine components such as carrier proteinsFurtherburgeoning new immunotherapies that use proteins such as si ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  3. Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain

    Amount: $3,000,000.00

    Scarab Genomics has established a unique, tiny footprint, extended bacterial fermentation process enabled by its reduced genome E. coli, for production of protein therapeutics, especially vaccine conj ...

    SBIRPhase II2019Department of Health and Human Services National Institutes of Health
  4. Lysis-free extraction of biopharmaceuticals from the periplasm of Clean Genome E. coli

    Amount: $1,649,139.00

    Thirty percent of recombinant therapeutic proteins are made in E. coli and include important vaccine components such as carrier proteins. Further, burgeoning new immunotherapies that use proteins such ...

    SBIRPhase II2019Department of Health and Human Services National Institutes of Health
  5. Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics' reduced genome E coli strains

    Amount: $154,222.00

    Scarab Genomics goal is to commercialize carrier proteins for conjugate vaccine manufacture This proposal focuses on two bacterial carrier proteins that have been approved by the FDA and that are in ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  6. Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics' reduced genome E. coli strains

    Amount: $1,584,682.00

    Scarab Genomicsgoal is to commercialize carrier proteins for conjugate vaccine manufactureThis proposal focuses on two bacterial carrier proteins that have been approved by the FDA and that are in use ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  7. Characterization of a low mutation rate E coli in extended fermentation

    Amount: $2,418,530.00

    DESCRIPTION provided by applicant Scarab Genomics was founded to improve E coli as an industrial organism by genome engineering These strains have stable genomes since all prophages transposable ...

    SBIRPhase II2016Department of Health and Human Services National Institutes of Health
  8. Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain

    Amount: $1,461,610.00

    DESCRIPTION provided by applicant CRM is an inactive form of diphtheria toxin that when conjugated to a vaccine antigen enhances immunity to generate long lasting vaccination against the antig ...

    SBIRPhase II2014Department of Health and Human Services National Institutes of Health
  9. Characterization of a low mutation rate E. coli in extended fermentation

    Amount: $282,618.00

    DESCRIPTION (provided by applicant): This application aims to test a new Scarab E. coli strain, MDS42pdu, for commercial fermentation to produce biopharmaceuticals, amino acids and biofuels. It is des ...

    SBIRPhase I2013Department of Health and Human Services National Institutes of Health
  10. A protease-deficient, low mutation rate E. coli for biotherapeutics production

    Amount: $1,624,414.00

    DESCRIPTION (provided by applicant): Biotherapeutics is a fast-growth sector in the pharmaceutical market with monoclonal antibodies accounting for almost 50% of the 100 billion USD spent each year on ...

    SBIRPhase II2013Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government